Suppr超能文献

对 73 名病因不明的入伍患者进行肝移植评估,发现一例迟发性溶酶体酸性脂肪酶缺乏症。

Evaluation of 73 Enlisted Patients for Liver Transplant with Unknown Etiology Reveals a Late-Diagnosed Case of Lysosomal Acid Lipase Deficiency.

机构信息

Unidade de Genética, Instituto da Criança, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo (FMUSP), Sao Paulo 05403-000, SP, Brazil.

Departamento de Anatomia Patológica, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo (FMUSP), Sao Paulo 05403-010, SP, Brazil.

出版信息

Int J Mol Sci. 2024 Aug 8;25(16):8648. doi: 10.3390/ijms25168648.

Abstract

Lysosomal acid lipase deficiency (LALD) varies from a severe infantile-onset form (Wolman disease) to a late-onset form known as cholesteryl ester storage disease (CESD), both of which are autosomal recessive disorders caused by biallelic pathogenic variants. We evaluated seventy-three patients enlisted for liver transplant (LT) at Instituto da Criança (HCFMUSP-Brazil) who were subjected to LAL activity measurement and Sanger sequencing analysis, resulting in a positive LALD diagnosis for only one of these individuals. This LALD patient presented recurrent diarrhea, failure to thrive, hepatomegaly, and dyslipidemia at the age of 4 months and liver failure by the age of 13 years. The LALD diagnosis confirmation was conducted at 24 years old due to low levels of LAL enzyme activity. The causal homozygous variant (NM_000235.4):c.266T>C(p.Leu89Pro) was identified, but the patient had already undergone his first LT at 18 years with several rejection episodes. Despite beginning treatment with sebelipase alfa at 26 years old (total of five infusions), this patient died at 28 years from complications after his second liver transplant. LALD is an important differential diagnosis in cases presenting with hepatomegaly, elevated liver enzymes, and dyslipidemia. Detecting low/absent LAL activity and identifying the causal variant are essential for diagnosis and specific treatment, as well as for appropriate genetic counseling. Early diagnosis, along with sebelipase alfa therapy, may improve the prognosis of affected patients.

摘要

溶酶体酸性脂肪酶缺乏症(LALD)的表现形式从严重的婴儿发病型(沃曼病)到晚发型,即胆固醇酯贮积病(CESD),两者均为常染色体隐性遗传病,由双等位基因致病性变异引起。我们评估了 73 名在巴西儿童研究所(HCFMUSP)登记接受肝移植(LT)的患者,他们接受了 LAL 活性测量和 Sanger 测序分析,只有其中 1 人被诊断为 LALD。这名 LALD 患者在 4 个月大时出现反复腹泻、生长不良、肝肿大和血脂异常,在 13 岁时出现肝功能衰竭。在 24 岁时由于 LAL 酶活性水平低而确认了 LALD 诊断。确定了致病纯合变异(NM_000235.4):c.266T>C(p.Leu89Pro),但该患者在 18 岁时已经进行了第一次 LT,并经历了多次排斥反应。尽管在 26 岁时开始接受 sebelipase alfa 治疗(总共进行了五次输注),但该患者在 28 岁时由于第二次肝移植后的并发症而死亡。LALD 是肝肿大、肝酶升高和血脂异常患者的重要鉴别诊断。检测低/无 LAL 活性并确定致病变异对于诊断和特异性治疗以及适当的遗传咨询至关重要。早期诊断加上 sebelipase alfa 治疗可能改善受影响患者的预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/916a/11354363/bb338fd453ca/ijms-25-08648-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验